Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)

Trends in Endocrinology and Metabolism

Volumn 21, Issue 7, 2010, Pages 419-427

  Chahal, Harvinder S ^a   Chapple, J Paul ^a   Frohman, Lawrence A ^b   Grossman, Ashley B ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCOCORTICOID RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN 90; HEPATITIS B VIRUS X PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE; SURVIVIN; THYROID HORMONE RECEPTOR BETA; TUMOR SUPPRESSOR PROTEIN; VIRUS PROTEIN; ARYL HYDROCARBON RECEPTOR-INTERACTING PROTEIN; SIGNAL PEPTIDE;

CARNEY COMPLEX; CLINICAL FEATURE; FAMILIAL CANCER; FAMILIAL ISOLATED PITUITARY ADENOMA; FAMILY STUDY; GENE INTERACTION; GENE MUTATION; GENE SILENCING; GENE TRANSLOCATION; GENETIC SCREENING; GENETIC TRAIT; HETEROZYGOTE; HUMAN; HYPOPHYSIS ADENOMA; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; CHROMOSOME 11; FEMALE; GENETICS; GERMLINE MUTATION; HYPOPHYSIS TUMOR; MALE; PATHOLOGY;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PITUITARY NEOPLASMS;

EID: 77954316421     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.02.007     Document Type: Review

References (92)

1. Beckers A., Daly A.F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol. 2007, 157:371-382.
2. Gadelha M.R., et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J. Clin. Endocrinol. Metab. 1999, 84:249-256.
3. Yamada S., et al. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 1997, 82:239-242.
4. Valdes-Socin, H. et al. (2000) Familial isolated pituitary adenomas not related to the MEN-1 syndrome: A study of 27 patients. 10th Meeting of the Belgian Endocrine Society. (abstract).
5. Daly A.F., et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab. 2006, 91:3316-3323.
6. Vierimaa O., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
7. Daly A.F., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 2007, 92:1891-1896.
8. Leontiou C.A., et al. The role of the AIP gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2008, 93:2390-2401.
9. Soares B.S., et al. Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J. Clin. Endocrinol. Metab. 2005, 90:6580-6587.
10. Gadelha M.R., et al. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J. Clin. Endocrinol. Metab. 2000, 85:707-714.
11. Petrulis J.R., Perdew G.H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact. 2002, 141:25-40.
12. Davies T.H., Sanchez E.R. FKBP52. Int. J. Biochem. Cell Biol. 2005, 37:42-47.
13. Kuzhandaivelu N., et al. XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation. Nucleic Acids Res. 1996, 24:4741-4750.
14. Georgitsi M., et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4101-4105.
15. Chahal, H.S. et al. (2008) The clinical and genetic characteristics of patients with familial isolated pituitary adenomas. Hormones, 11th International Workshop of MEN meeting, Delphi 7 (Suppl. 2), O8.
16. Igreja, S.C. et al. (2010) Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum. Mut., In Press.
17. Beckers, A. et al. (2008) Germline AIP, MEN1, PRKAR1A, CDKN1B (p27Kip1) and CDKN2C (p18INK4c) gene mutations in a large cohort of pediatric patients with pituitary adenomas occurring in isolation or with associated syndromic features. Proceedings of the 90th Annual Meeting of the Endocrine Society, OR38-1.
18. Naves L.A., et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur. J. Endocrinol. 2007, 157:383-391.
19. Khoo S.K., et al. Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. Endocr. Relat. Cancer 2009, 16:1057-1063.
20. Jennings J., et al. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. Eur. J. Endocrinol. 2009, 161:799-804.
21. Georgitsi M., et al. Large genomic deletions of aryl hydrocarbon receptor interacting protein (AIP) gene in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 2008, 93:4146-4151.
22. Barlier A., et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2007, 92:1952-1955.
23. Cazabat L., et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol. 2007, 157:1-8.
24. Luccio-Camelo D.C., et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur. J. Endocrinol. 2004, 150:643-648.
25. Toledo, R.A. et al. (2008) Familial somatotropinoma and adrenocortical carcinoma due to a novel germline mutation and loss of the wild-type allele of the AIP gene. Proceedings of the 90th Annual Meeting of the Endocrine Society, P1-488.
26. Bolger G.B., et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 2003, 278:33351-33363.
27. Buchbinder S., et al. Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas. Exp. Clin. Endorcrinol. Diabetes 2008, 116:625-628.
28. Yaneva, M. et al. (2008) Aryl hydrocarbon receptor interacting protein gene mutations in bulgarian FIPA and young sporadic pituitary adenoma patients. Proceedings of the 90th Annual Meeting of the Endocrine Society, P3-520.
29. Frohman L.A., Eguchi K. Familial acromegaly. Growth Horm. IGF Res. 2004, 14(Suppl. A):S90-S96.
30. Iwata T., et al. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin. Endocrinol. (Oxf.) 2007, 66:499-502.
31. Montanana, C.F. et al. (2008) Occurrence of AIP mutations in sporadic pituitary adenomas and familial isolated pituitary adenomas kindreds in Valencia, Spain. Proceedings of the 90th Annual Meeting of the Endocrine Society, P3-775.
32. Raitila A., et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr. Relat. Cancer 2007, 14:901-906.
33. Georgitsi M., et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin. Endocrinol. (Oxf.) 2008, 69:621-627.
34. Toledo, R.A. et al. (2008) The role of AIP gene in Brazilian patients with sporadic and familial acromegaly. Proceedings of the 90th Annual Meeting of the Endocrine Society, P3-738.
35. Vargiolu M., et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J. Clin. Endocrinol. Metab. 2009, 94:2571-2578.
36. Lin B.C., et al. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J. Biol. Chem. 2007, 282:35924-35932.
37. Lin B.C., et al. A hypomorphic allele of aryl-hydrocarbon receptor-associated-9 produces a phenocopy of the Ahr null. Mol. Pharmacol. 2008, 74:1367-1371.
38. Heliovaara E., et al. The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am. J. Pathol. 2009, 175:2501-2507.
39. Leontiou, C.A. et al. (2008) AIP - a tumour suppressor gene in familial pituitary tumours, affects the cell cycle proteins and the caspase cascade. Hormones, 11th International Workshop of MEN meeting, Delphi 7 (Suppl. 2), O9.
40. Bunger M.K., et al. Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor. J. Biol. Chem. 2003, 278:17767-17774.
41. Tomita S., et al. T cell-specific disruption of arylhydrocarbon receptor nuclear translocator (Arnt) gene causes resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced thymic involution. J. Immunol. 2003, 171:4113-4120.
42. Walisser J.A., et al. Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele. J. Biol. Chem. 2004, 279:16326-16331.
43. Barouki R., et al. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007, 581:3608-3615.
44. Perdew G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J. Biol. Chem. 1988, 263:13802-13805.
45. Carver L.A., Bradfield C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J. Biol. Chem. 1997, 272:11452-11456.
46. Ma Q., Whitlock J.P. A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Biol. Chem. 1997, 272:8878-8884.
47. Meyer B.K., et al. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol. Cell Biol. 1998, 18:978-988.
48. Kazlauskas A., et al. Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J. Biol. Chem. 1999, 274:13519-13524.
49. Gottlieb E., Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 2005, 5:857-866.
50. Ramadoss P., Perdew G.H. The transactivation domain of the Ah receptor is a key determinant of cellular localization and ligand-independent nucleocytoplasmic shuttling properties. Biochemistry 2005, 44:11148-11159.
51. Yano M., et al. AIP is a mitochondrial import mediator that binds to both import receptor Tom20 and preproteins. J. Cell Biol. 2003, 163:45-56.
52. Ohtake F., et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007, 446:562-566.
53. Matikainen T., et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat. Genet. 2001, 28:355-360.
54. Weinberg C.R., et al. Reduced fecundability in women with prenatal exposure to cigarette smoking. Am. J. Epidemiol. 1989, 129:1072-1078.
55. Jurisicova A., et al. Maternal exposure to polycyclic aromatic hydrocarbons diminishes murine ovarian reserve via induction of Harakiri. J. Clin. Invest. 2007, 117:3971-3978.
56. Ciolino H.P., et al. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998, 58:5707-5712.
57. Weiss C., et al. TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A. Oncogene 2008, 27:2198-2207.
58. Marlowe J.L., Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell Biochem. 2005, 96:1174-1184.
59. Mulero-Navarro S., et al. Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model. J. Biol. Chem. 2005, 280:28731-28741.
60. Ma Q., Whitlock J.P. The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol. Cell Biol. 1996, 16:2144-2150.
61. Alexander D.L., et al. Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J. Cell Sci. 1998, 111:3311-3322.
62. 2/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol. Pharmacol. 2000, 57:1056-1063.
63. Shimba S., et al. Overexpression of the aryl hydrocarbon receptor (AhR) accelerates the cell proliferation of A549 cells. J. Biochem. (Tokyo) 2002, 132:795-802.
64. Moennikes O., et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 2004, 64:4707-4710.
65. Vondracek J., et al. Aryl hydrocarbon receptor-activating polychlorinated biphenyls and their hydroxylated metabolites induce cell proliferation in contact-inhibited rat liver epithelial cells. Toxicol. Sci. 2005, 83:53-63.
66. Marlowe J.L., et al. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Mol. Biol. Cell 2008, 19:3263-3271.
67. Ge N.L., Elferink C.J. A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J. Biol. Chem. 1998, 273:22708-22713.
68. Huang G., Elferink C.J. Multiple mechanisms are involved in Ah receptor-mediated cell cycle arrest. Mol. Pharmacol. 2005, 67:88-96.
69. Pang P.H., et al. Molecular mechanisms of p21 and p27 induction by 3-methylcholanthrene, an aryl-hydrocarbon receptor agonist, involved in antiproliferation of human umbilical vascular endothelial cells. J. Cell. Physiol. 2008, 215:161-171.
70. Jaffrain-Rea M.L., et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer 2009, 16:1029-1043.
71. Bertherat J., et al. The cyclic adenosine 3ó,5ó-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol. Endocrinol. 1995, 9:777-783.
72. Oesch-Bartlomowicz B., et al. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9218-9223.
73. de Oliveira S.K., et al. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J. Biol. Chem. 2007, 282:13656-13663.
74. Horvath A., et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 2006, 38:794-800.
75. Horvath A., et al. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N. Eng. J. Med. 2008, 358:750-752.
76. Horvath A., et al. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur. J. Hum. Genet. 2008, 16:1245-1253.
77. Yang Q., et al. The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol. Sci. 2008, 101:132-139.
78. Sumanasekera W.K., et al. Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. J. Biol. Chem. 2003, 278:4467-4473.
79. Carver L.A., et al. Characterization of the Ah receptor-associated protein, ARA9. J Biol. Chem 1998, 273:33580-33587.
80. Laenger A., et al. XAP2 inhibits glucocorticoid receptor activity in mammalian cells. FEBS Lett. 2009, 583:1493-1498.
81. Froidevaux M.S., et al. The co-chaperone XAP2 is required for activation of hypothalamic thyrotropin-releasing hormone transcription in vivo. EMBO Rep. 2006, 7:1035-1039.
82. Baccarelli A., et al. Neonatal thyroid function in Seveso 25 years after maternal exposure to dioxin. PLoS. Med. 2008, 5:e161.
83. Pesatori A., et al. Aryl hydrocarbon receptor interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur. J. Endocrinol. 2008, 159:699-703.
84. Krauer K.G., et al. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 2004, 23:1342-1353.
85. Kashuba E., et al. Epstein-Barr virus encodes nuclear protein EBNA-3 binds XAP-2, a protein associated with hepatitis B virus X antigen. Oncogene 2000, 19:1801-1806.
86. 13-mediated signalling in mammalian physiology and disease. Trends Pharmacol. Sci. 2008, 29:582-589.
87. 13 interact with Ser/Thr protein phosphatase type 5 and stimulate its phosphatase activity. Curr. Biol. 2002, 12:1353-1358.
88. Nakata A., et al. G-protein signalling negatively regulates the stability of aryl hydrocarbon receptor. EMBO Rep. 2009, 10:622-628.
89. Kang B.H., Altieri D.C. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J. Biol. Chem. 2006, 281:24721-24727.
90. Canibano C., et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 2007, 26:2015-2028.
91. Kazlauskas A., et al. The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor. J. Biol. Chem. 2000, 275:41317-41324.
92. Kashuba E., et al. Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with hepatitis B virus X antigen. Oncogene 2000, 19:1801-1806.